^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IL-2 stimulant

    Related drugs:
    3d
    First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL-2 in Patients with High-Grade Serous Ovarian Carcinoma. (PubMed, Clin Cancer Res)
    In patients with HGSOC, AVB-001 is safe and effectively activates cytotoxic T cells, supporting further investigation of this locoregional immunotherapy.
    P1 data • Journal • PD(L)-1 Biomarker • IO biomarker • First-in-human
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule) • IL2 (Interleukin 2)
    |
    AVB-001
    3d
    CUE-101with Pembrolizumab for LA-HPV+HNSCCs (clinicaltrials.gov)
    P2, N=30, Recruiting, Yale University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    Keytruda (pembrolizumab) • CUE-101
    3d
    ProbeTILity: A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC (clinicaltrials.gov)
    P1/2, N=12, Recruiting, Curacell Holding AB
    Trial initiation date • First-in-human
    |
    Keytruda (pembrolizumab) • Proleukin (aldesleukin)
    4d
    R10597-ONC-22114: A First-In-Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination with Cemiplimab Works in Adult Participants Who Have Cancer with Tumors that Have Spread in Their Body (2025-523399-22-00)
    P1/2, N=52, Not yet recruiting, Regeneron Pharmaceuticals Inc.
    New P1/2 trial • First-in-human
    |
    Libtayo (cemiplimab-rwlc)
    5d
    Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P2, N=480, Recruiting, Shanghai Junshi Bioscience Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Loqtorzi (toripalimab-tpzi) • AWT020
    8d
    PROTA: Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. (clinicaltrials.gov)
    P1/2, N=29, Active, not recruiting, TILT Biotherapeutics Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed • Platinum resistant
    |
    Keytruda (pembrolizumab) • pegylated liposomal doxorubicin • igrelimogene litadenorepvec (TILT-123)
    8d
    A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=96, Not yet recruiting, Philogen S.p.A.
    New P1 trial
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • RAS wild-type
    |
    Jakafi (ruxolitinib) • darleukin (L19IL2)
    14d
    Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=138, Not yet recruiting, Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
    New P1 trial • First-in-human
    23d
    Aerosolized Aldesleukin in Treating Patients With Lung Metastases (clinicaltrials.gov)
    P1, N=70, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Apr 2026 --> Apr 2029 | Trial primary completion date: Apr 2026 --> Apr 2029
    Trial completion date • Trial primary completion date
    |
    Proleukin (aldesleukin)
    1m
    Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study. (PubMed, J Immunother Cancer)
    The combination of FAP-IL2v plus atezolizumab with or without bevacizumab was consistent with the known safety profile of the individual drugs. The maximum tolerated dose was not reached, with a recommended FAP-IL2v dose of 10 mg. ORR was higher among patients receiving the triplet therapy compared with the doublet. Pharmacodynamic results were consistent with the mechanism of action of IL-2, supporting further research in this field.
    Clinical • P1 data • Journal • PD(L)-1 Biomarker
    |
    CD8 (cluster of differentiation 8) • FAP (Fibroblast activation protein, alpha)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • simlukafusp alfa (RG7461)
    1m
    RIOT 4B: Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors (clinicaltrials.gov)
    P1, N=10, Recruiting, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    Proleukin (aldesleukin)
    1m
    Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer (clinicaltrials.gov)
    P1, N=210, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2033 --> Feb 2029 | Trial primary completion date: Jun 2031 --> Feb 2029
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • SLATE-KRAS